Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Erasca entered into a clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 alongside the PRMT5 inhibitor navlimetostat in a Phase 1/2 trial for MTAP-deleted pancreatic cancer.
Why it matters — The collaboration and planned trial evaluate ERAS-0015 in combination with navlimetostat for this cancer type.